T-Cypher Bio
UK - OxfordBiotechnology
Focus: T-Cypher Bio is a newly-formed (2024) UK-based biotechnology company specializing in TCR-based therapeutic candidates for oncology. The company is listed as public-stage but remains pre-revenue with no disclosed pipeline programs or products.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at T-Cypher Bio?
AI assessmentHigh-risk, early-stage opportunity suitable only for founders/senior scientists willing to take a multi-year bet on an unproven TCR platform with no near-term milestones.
Why Work Here
- Ground-floor opportunity at a newly-launched (2024) TCR therapeutics platform with public-market backing in a high-conviction oncology modality.
- Oxford headquarters provides access to leading UK academic networks and immunology talent clusters.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for T-Cypher Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.